Premium
Effects of trans ‐resveratrol on hypertension‐induced cardiac hypertrophy using the partially nephrectomized rat model
Author(s) -
Liu Zhaoping,
Song Yan,
Zhang Xiaopeng,
Liu Zeqing,
Zhang Wenzhong,
Mao Weifeng,
Wang Wei,
Cui Wenming,
Zhang Xin,
Jia Xudong,
Li Ning,
Han Chi,
Liu Changxing
Publication year - 2005
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2005.04299.x
Subject(s) - resveratrol , medicine , endocrinology , cardiac hypertrophy , angiotensin ii , muscle hypertrophy , blood pressure , nitric oxide , nephrectomy , left ventricular hypertrophy , in vivo , endothelin receptor , endothelin 1 , kidney , pharmacology , receptor , biology , microbiology and biotechnology
Summary 1. trans ‐Resveratrol (resveratrol) has been shown to have beneficial effects on the cardiovascular system in a number of studies. It is, however, unclear whether this naturally occurring compound can protect against cardiac hypertrophy. The aim of the present study was to investigate the effects of resveratrol on cardiac hypertrophy in vivo and the potential underlying mechanisms involving endothelin (ET), angiotensin (Ang) II and nitric oxide (NO) in partially nephrectomized rats. 2. Animal models bearing cardiac hypertrophy were replicated in male Sprague‐Dawley rats following partial nephrectomy (PNX). Resveratrol (10 or 50 mg/kg) was administered to rats by gavage for 4 weeks. Simultaneous PNX and sham operation controls were simultaneously established in the present study. The systolic blood pressure (SBP) of rats was measured at baseline and, along with heart weight, after 4 weeks treatment. Serum ET‐1, AngII and NO concentrations were determined. 3. In the present study, it was shown that, compared with rats in the sham‐operated group, rats in the PNX group had significantly higher SBP (154.1 ± 22.7 mmHg), heart weight (1.69 ± 0.24 g) and serum ET‐1 (125.70 ± 26.27 pg/mL) and AngII serum concentrations (743.63 ± 86.50 pg/mL), whereas serum NO concentrations were lower (21.1 ± 6.9 μmol/L; all P < 0.05). These values in the sham control group were 114 ± 10 mmHg, 1.28 ± 0.13 g, 52.44 ± 21.85 pg/mL, 528.7 ± 158.5 pg/mL and 53.21 ± 23.87 µmol/L, respectively. After 4 weeks treatment with 50 mg/kg resveratrol, SBP, heart weight and ET‐1 and AngII concentrations had decreased to 135.4 ± 15.8 mmHg, 1.39 ± 0.15 g, 97.11 ± 26.74 pg/mL and 629.64 ± 116.18 pg/mL, respectively. However, the serum NO concentration had increased to 40.1 ± 14.6 μmol/L. These values were significantly different from those obtained for the PNX group. 4. In conclusion, trans ‐resveratrol appears to be able to protect against the increase in SBP and subsequent cardiac hypertrophy in vivo and the mechanisms responsible may involve, at least in part, modulation of NO, AngII and ET‐1 production.